Who is sponsoring NCT05338723?

NCT05338723 is sponsored by Tanta University.

What drugs are being tested in NCT05338723?

Interventions in NCT05338723: Rosuvastatin 20mg.

What condition does NCT05338723 study?

NCT05338723 studies Chemotherapy-induced Cardiotoxicity, Breast Cancer.

Is NCT05338723 still recruiting?

NCT05338723 is currently completed. Last updated 28 February 2024.

Last reviewed 2024-02-28 · How we verify

NCT05338723

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients

Completed Phase 3 Last updated 28 February 2024

What this trial tests

Phase 3 trial testing Rosuvastatin 20mg in Chemotherapy-induced Cardiotoxicity in 50 participants. Completed in 15 September 2023.

Timeline

15 September 2020

Primary endpoint
15 September 2023

15 September 2023

Quick facts

Lead sponsor	Tanta University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	50
Start date	15 September 2020
Primary completion	15 September 2023
Estimated completion	15 September 2023
Sites	1 location across Egypt

Drugs / interventions tested

Rosuvastatin 20mg — full drug profile →

Conditions studied

Chemotherapy-induced Cardiotoxicity — all drugs for Chemotherapy-induced Cardiotoxicity →
Breast Cancer — all drugs for Breast Cancer →

Sponsor

Tanta University

Who can join

Adults 25 to 75, female only, with Chemotherapy-induced Cardiotoxicity or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the possible role of rosuvastatin in protection against cardiotoxicity in HER2 positive breast cancer patients receiving doxorubicin sequential with trastuzumab.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Navigating cancer therapy induced cardiotoxicity: From pathophysiology to treatment innovations.
Tetterton-Kellner J, Jensen BC, Nguyen J. · · 2024 · cited 20× · PMID 38901637 · DOI 10.1016/j.addr.2024.115361
Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial.
Kettana KM, El-Haggar SM, Alm El-Din MA, El-Afify DR. · · 2024 · cited 7× · PMID 38977536 · DOI 10.1007/s12032-024-02426-1

Verify or expand the search:

Other trials of Rosuvastatin 20mg

Trials testing the same drug.

NCT06358313 — Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Moderate and Moderate-to-severe Stroke · Phase 3 · recruiting
NCT06360120 — Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke · Phase 3 · recruiting
NCT06105060 — Clinical Effects of New Approach on Patients With Non-alcoholic Steatohepatitis · EARLY_PHASE1 · completed
NCT04499859 — Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI · Phase 4 · recruiting
NCT03988101 — Role of Statin in Venous Dysfunction in Patients With Venous Thromboembolism Event · Phase 4 · completed

Other Tanta University trials

Trials by the same sponsor.

NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
NCT06966856 — This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcti · Phase 3 · not yet recruiting
NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
NCT07498998 — Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome · NA · not yet recruiting
NCT07114250 — Comparative Study Between Spinal Anesthesia Versus General Anesthesia in Supine Percutaneous Nephrolithotomy Operation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05338723 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tanta University
Last refreshed: 28 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05338723.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing